In oncology drug discovery, rapidly assessing whether a candidate warrants further advancement is critical to resource allocation. Cell-based efficacy screening enables in vitro observation of cellular states, functional phenotypes, and molecular mechanisms, informing whether a research direction merits continued investment. Alfa Cytology provides integrated, oncology-focused screening solutions, from cell model selection and treatment optimization to functional phenotyping and mechanistic analysis, supporting milestone decisions before in vivo studies.
In vitro cell-based efficacy screening is an efficacy assessment strategy implemented early in drug discovery, centered on speed and resource efficiency. Its design philosophy departs from the exhaustive data-generation paradigm of conventional long-term in vivo efficacy studies, adopting instead a highly streamlined experimental protocol: a limited number of cell models and key treatment conditions, combined with high-sensitivity functional and molecular readouts (e.g., viability/proliferation assays, apoptosis analysis, migration and invasion assays, immunofluorescence, or Western blot), to rapidly quantify key metrics such as cell viability, proliferation inhibition, apoptotic fraction, and invasive capacity. The overall study timeline can be compressed to days to weeks. Its primary purpose is not to replace subsequent, more rigorous formal in vivo efficacy studies, but to serve as an efficient "decision filter"—enabling research teams to complete candidate triage, define potential effective concentration ranges, and identify promising lead candidates before committing to large-scale, long-term validation.
Fig. 1 Model of the developed platform for drug screening. (Saraiva DP, et al.; 2020)
Alfa Cytology's integrated cell-based efficacy screening solutions are not delivered as fixed, off-the-shelf assay lists. Instead, study design is stratified according to project type—drug screening, cytotoxicity assessment, tumor model development, functional phenotype validation, mechanistic exploration, omics validation, product functional evaluation, or pre-in vivo screening. Services include, but are not limited to:
Primary Screening and Phenotype Confirmation
We conduct primary screening of candidate drugs, treatment conditions, stimuli, and time windows using CCK-8, ATP viability assays, cell counting, morphological observation, basic cytotoxicity testing, and dose-gradient analysis. Phenotype confirmation is performed across endpoints such as proliferation inhibition, increased cell death, enhanced migration and invasion, emergence of drug-resistant phenotypes, and altered sensitivity to immune-mediated killingm, helping clients determine early whether a research direction merits further investigation.
Functional and Cell–Cell Interaction Validation
Functional assays are used to determine whether phenotypic changes translate into functional consequences, including tumor cell invasive capacity, immune cell killing efficacy, endothelial barrier integrity, and clonogenic potential. We also provide model validation services using direct co-culture, Transwell, conditioned medium, and immune cell–tumor cell interaction systems, helping clients dissect complex interaction effects such as cell–cell communication, microenvironmental influence, and immune-mediated killing.
Mechanistic study
Building on an established phenotype, pathway marker analysis, protein and RNA-level profiling, inhibitor/agonist intervention, genetic manipulation, co-localization analysis, or functional rescue experiments can be incorporated as needed to elucidate the mechanisms underlying the observed phenotype.
Efficacy Evaluation
We provide in vitro efficacy evaluation of candidate drugs, covering efficacy, toxicity boundaries, dose windows, combination regimens, and preliminary direction-of-effect assessment. Study design emphasizes experimental reproducibility, appropriate detection windows, and statistical rigor, providing a basis for milestone decision-making in R&D.
All assays below are modular and can be selected, combined, or adapted to your specific project goals. Each assay type is designed to answer a distinct biological question, including viability, proliferation, cell death, migration, barrier function, immune activity, metabolism, senescence, or multicellular interactions, so that readouts remain interpretable and directly aligned with your research objectives.
Cell Viability and Cytotoxicity Assessment
Common methods include CCK-8, MTT, ATP viability assays, cell counting, and morphological observation, suitable for assessing the effects of candidate drugs on the overall state of tumor cells. Such results should serve as a basis for preliminary anti-tumor drug screening and should not be used alone as a substitute for functional conclusions.
Proliferation and Cell Cycle
Common methods include EdU, BrdU, Ki-67, colony formation assays, and flow cytometric cell cycle analysis, used to determine whether tumor cells have genuinely entered a proliferative state or undergone cell cycle arrest. Applicable to anti-tumor drug efficacy evaluation, tumor proliferation mechanism studies, and gene function validation.
Cell Death and Damage
Common methods include Annexin V/PI, TUNEL, live/dead cell staining, LDH release, caspase activity, mitochondrial membrane potential, and death-related protein detection, suitable for determining the stage of tumor cell death induced by anti-tumor drugs, the extent of damage, and the likely mode of death.
Migration, Invasion, and Adhesion
Common methods include wound healing assays, Transwell migration assays, Matrigel invasion assays, adhesion assays, and cytoskeletal observation, suitable for evaluating the inhibitory effects of drugs on tumor cell metastasis, invasion, and adhesion.
Barrier Function and Angiogenesis
Common methods include tube formation assays, TEER measurements, permeability assays, tight junction protein localization, and endothelial activation marker analysis, suitable for evaluating the effects of drugs on tumor angiogenesis, as well as studies related to tumor endothelial barrier function, drug permeability, and inflammatory damage.
Immune Function
Common methods include phagocytosis assays, killing assays, polarization analysis, cytokine detection, antigen presentation analysis, and flow cytometric immunophenotyping, suitable for evaluating the killing and immunomodulatory functions of macrophages, T cells, NK cells, dendritic cells, and other immune cells against tumor cells.
Metabolism and Organelle Function
Common methods include ROS detection, mitochondrial membrane potential, ATP detection, lipid droplet staining, autophagy detection, lysosomal function, and endoplasmic reticulum stress detection, suitable for evaluating tumor cell stress, metabolic abnormalities, organelle damage, and toxicity mechanisms induced by anti-tumor drugs.
Senescence and Chronic Damage
Common methods include SA-β-gal staining, p16, p21, SASP factors, and lipid accumulation detection, suitable for studies on tumor cell senescence, chronic damage, and therapy resistance under long-term anti-tumor drug exposure.
Multicellular Interactions and Paracrine Signaling
Common methods include direct co-culture, Transwell, and conditioned medium treatment, suitable for analyzing tumor–stromal cell communication, immune–tumor interactions, tumor microenvironment (TME) regulation, and paracrine-mediated drug resistance mechanisms.
Our technology platforms underpin every stage of cell-based research, from model development to imaging, flow cytometry, and co-culture, ensuring reproducibility and data quality across all assays.
Cell Culture and Model Development Platform
Supports routine cell line culture, primary cell culture, drug treatment, inflammatory stimulation, hypoxia/reoxygenation, oxidative stress, lipid metabolism dysregulation, fibrosis induction, immune polarization, injury repair, differentiation induction, and establishment of co-culture systems. This platform is suited to early-stage model development and optimization of treatment conditions, and serves as the foundation for subsequent functional assays and mechanistic validation.
Cell Phenotype Analysis Platform
Supports assessment of cell proliferation, viability, cytotoxicity, cell cycle, apoptosis, necrosis, autophagy, migration, invasion, colony formation, adhesion, senescence, differentiation, polarization, phagocytosis, lipid droplets, foam cell formation, and cell–cell interactions. This platform translates research directions into observable, quantifiable, and comparable cell phenotype results.
Microscopy Imaging Platform
Inverted phase-contrast microscopy enables observation of cell morphology, adhesion status, and growth status; fluorescence microscopy supports immunofluorescence, fluorescent probe, and subcellular localization analysis; confocal microscopy enables subcellular localization, co-localization, organelle observation, and multiplex imaging. The imaging platform enhances the visual presentation of results and provides image-based evidence for projects.
Flow Cytometry Platform
Flow cytometry supports analysis of apoptosis, cell cycle, reactive oxygen species (ROS), mitochondrial membrane potential, immunophenotyping, cell polarization, cell subpopulations, multiparameter single-cell quantification, and immune function. This platform is suited to heterogeneous cell populations, immune cells, co-culture systems, and projects requiring single-cell-level quantification.
Microplate Reader and Multifunctional Microplate Platform
Supports CCK-8, MTT, ATP, ELISA, enzyme activity, ROS, metabolic markers, fluorescence, luminescence, and absorbance detection, suitable for drug screening, batch sample testing, cytotoxicity assessment, and secreted factor analysis. This platform is suited to high-throughput screening for industry clients as well as primary screening and quantitative analysis for academic projects.
Co-Culture and Cell Interaction Platform
Supports direct co-culture, Transwell, conditioned medium, immune cell interactions, tumor–stromal interactions, epithelial–fibroblast interactions, endothelial–pericyte interactions, and macrophage–fibroblast interactions. This platform is suited to studying cell–cell communication, microenvironmental influence, inflammatory amplification, fibrotic interactions, immune-mediated killing, and altered drug responses.
Every project begins at a different stage—some with only an indication direction, others with candidate compounds, preliminary data, or existing results. Alfa Cytology's pathways below outline common starting points and the corresponding recommended next steps, helping you quickly locate the most relevant entry point and plan an efficient route forward with our support.
Indication direction only, no cell model yet
Define research objectives → Select indication-relevant cell model → Design treatment conditions → Primary phenotype screening → Key functional validation → Mechanistic study or transition to in vivo studies.
Drug or candidate compound available, in vitro evaluation needed
Select cell type → Dose and time gradients → Viability/toxicity screening → Proliferation, death, or key functional validation → Mechanistic marker assessment as needed.
Cell viability data available but difficult to interpret
Verify seeding density and time points → Direct cell counting or live/dead assay → Stratified analysis of proliferation, death, and cell cycle → Mechanistic or functional supplementation.
Sequencing data available, in vitro validation needed
Candidate pathway selection → Cell model adaptation → qPCR/Western blot validation → Functional assays → Data integration
Disease-relevant cell model needed
Disease background analysis → Selection of inducing factors → Model marker confirmation → Phenotype validation → Functional and mechanistic assessment.
Drug screening or product validation needed
Assay system selection → Dose window optimization → Batch testing → Data analysis → Candidate condition selection → Interim report delivery.
Cell interactions or microenvironmental effects to be studied
Cell pair selection → Direct or indirect co-culture → Primary cell endpoint design → Secreted factor or functional assays → Mechanistic dissection.
Improved disease relevance of the model needed
Review of conventional cell model results → Supplementation with primary cells or co-culture systems → Functional validation → Comparative analysis.
One-Stop Solution
Even when a client has no defined experimental roadmap and only an indication direction, a candidate drug, a cell type, or preliminary observations, Alfa Cytology can still engage: we first define the project type, then design the model selection, assay endpoints, and a phased execution plan.
Custom Design
Different indications, cell types, treatment factors, and application goals require different cell models and assay combinations. Alfa Cytology does not apply fixed assay lists to every project; instead, we design the most appropriate experimental plan around the intended use of the project.
Integrated Workflow
Cell-based projects involve model development, functional assays, analytical platforms, and data organization. Alfa Cytology integrates these steps, reducing client-side fragmentation and enhancing deliverable usability for project reporting, R&D records, and downstream experiments.
Alfa Cytology offers flexible cell-based efficacy screening solutions tailored to project needs, whether for primary screening of a single candidate, dose-range exploration, or triage of a small lead series. To learn more about our cell-based efficacy screening services for oncology candidates, please feel free to contact us. our technical team will assist in evaluating your study plan and designing a phased execution pathway.
References
For research use only.
Alfa Cytology, a preclinical research solution provider, provides its clients with one-stop solutions to accelerate cancer therapeutics discovery and development.
Copyright © 2026 Alfa Cytology. All rights reserved.